US EditionPublished • loading... • Updated
Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections
Novo Nordisk alleges Hims & Hers sold unapproved compounded semaglutide with impurities up to 86%, seeking a permanent sales ban and damages to protect patients and patents.
- Novo Nordisk is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of Novo's new Wegovy obesity pill and injections in the U.S.
- Novo accused Hims of deceiving patients and putting their health at risk by selling compounded versions of its drugs without verifying safety, efficacy and quality.
- The FDA announced plans to take legal action against Hims for selling an unapproved $49 knockoff of Wegovy, and Hims scrapped those plans.
Insights by Ground AI
Podcasts & Opinions
27 Articles
27 Articles
Novo Nordisk sues Hims over scrapped $49 weight-loss pill copy
Novo Nordisk sued Hims and Hers Health on Monday over patent infringement after the U.S. telehealth firm launched, then canceled, a US$49 copy of Novo’s weight-loss pill Wegovy following backlash from the U.S. Food and Drug Administration.
·Canada
Read Full Article
Coverage Details
Total News Sources27
Leaning Left6Leaning Right4Center10Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 30%
C 50%
R 20%
Factuality
To view factuality data please Upgrade to Premium
